Natera Expands Lawsuit Against NeoGenomics to Include Additional Patent

MT Newswires Live
2024-12-17

Natera (NTRA) said Tuesday that it has expanded its patent infringement lawsuit against NeoGenomics (NEO) related to the latter's modified version of RaDaR tests for molecular residual disease.

Natera said the District Court for the Middle District of North Carolina has granted its request to include an additional patent as part of the lawsuit.

Natera is asking the court to award it full remedies against NeoGenomics' current RaDaR test offering, including injunctive relief.

NeoGenomics did not immediately respond to a request for comment from MT Newswires.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10